My ePortfolio Register   

Tumour DNA in blood may serve as prognostic marker of pancreatic cancer

The presence of circulating tumor DNA (ctDNA) isolated from blood samples of patients with pancreatic adenocarcinoma was associated with poor outcomes, according to data published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

The incidence of pancreatic adenocarcinoma is on the rise in Western countries, and prognosis remains very poor. 

Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2030, behind lung cancer, and is therefore considered a public health problem, notes lead author Jean-Baptiste Bachet, MD, PhD, from the Gastroenterology and Digestive Oncology Department at Sorbonne University, and the Centre Universitaire des Saints-Pères, both in Paris, France.

There are several challenges to conducting translational research on pancreatic cancer, including the difficulty in obtaining tumour samples from patients, because of which, most studies have been limited to patients with resectable disease until now, Bachet explained.

However, only 10 to15 percent of patients with pancreatic adenocarcinoma have resectable disease at diagnosis.

Identification of robust prognostic or predictive biomarkers are urgently needed for all patients with pancreatic adenocarcinoma, whatever the stage of the disease, he said.

"Our study confirms, in one of the largest reported series, the feasibility of detecting ctDNA in patients with pancreatic adenocarcinoma using a specific next-generation sequencing (NGS) analysis method that allows us to screen a large number of genes," said Bachet. "Our study also confirms the strong prognostic value of the presence of ctDNA and of its level, when detected, in advanced pancreatic adenocarcinoma," he added.

Bachet and team initiated a prospective study five years ago to collect blood samples from patients with pancreatic adenocarcinoma with the goal of identifying blood-based biomarkers to overcome the challenge of limited availability of tumour samples for research purposes.

In this study, the researchers analyzed blood samples from 135 patients with pancreatic adenocarcinoma; 31 had resectable tumours, 36 had locally advanced disease (LA), and 68 had metastatic disease (M).

They extracted DNA from the plasma samples and used a specific NGS analysis method to detect low-allele frequency mutations.

They also screened all plasma samples for the three most frequent KRAS mutations in pancreatic adenocarcinoma, besides several other mutations, by picoliter droplet-based digital PCR (dPCR).

In multivariate analysis, the presence of ctDNA was an independent prognostic biomarker in patients with advanced disease, and it also correlated with the stage of the disease and the grade of tumour differentiation.

Of the 104 patients with advanced disease, 50 had detectable ctDNA (LA, 17 percent; M, 65 percent).

After a median follow-up of 34.2 months, 76 died.

Overall survival (OS) was 19 months in patients with no detectable ctDNA, versus 6.5 months in those with ctDNA.

When patients with advanced disease were grouped into tertiles based on the frequency of mutations in the ctDNA, there was a significant dose-response relationship with OS: 18.9 months for those in the lowest tertile, 7.8 months for those those in the middle, and 4.9 months for those in the highest tertile.

Of the 31 patients with resectable disease, six had detectable ctDNA.

After a median follow-up of 33.3 months, 23 had disease recurrence and 13 of them died.

Disease-free survival was 17.6 months in patients with no detectable ctDNA, versus 4.6 months in those with ctDNA; OS was 32.2 months versus 19.3 months.

A strong correlation was observed between the results obtained with NGS and droplet-based dPCR to study KRAS, confirming that their NGS strategy is pertinent, Bachet said.

"Our results demonstrate the utility of circulating biomarkers in subclassifying cancers and managing treatment," Bachet noted. "We need to confirm these results in prospective clinical trials to better assess the predictive value of this biomarker in light of the dynamic biological changes that occur during treatment."

 As a limitation to the study, in the subgroup of patients who had curative-intent resection, blood samples were not collected before surgery so the researchers did not have pre-operative ctDNA data for these patients.

Source: Clinical Cancer Research



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence